Physicochemical Properties
| Molecular Formula | C30H41NO3 |
| Molecular Weight | 463.65144 |
| Exact Mass | 463.309 |
| CAS # | 129024-87-9 |
| PubChem CID | 6443994 |
| Appearance | Typically exists as solid at room temperature |
| LogP | 8.074 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 17 |
| Heavy Atom Count | 34 |
| Complexity | 687 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(NCCC1=CC=C(O)C(O)=C1)=O |
| InChi Key | HXJMZRVSTICUKC-KUBAVDMBSA-N |
| InChi Code | InChI=1S/C30H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-30(34)31-25-24-27-22-23-28(32)29(33)26-27/h3-4,6-7,9-10,12-13,15-16,18-19,22-23,26,32-33H,2,5,8,11,14,17,20-21,24-25H2,1H3,(H,31,34)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18- |
| Chemical Name | (4Z,7Z,10Z,13Z,16Z,19Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]docosa-4,7,10,13,16,19-hexaenamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | NMI 8739 is a dopamine D2 autoreceptor agonist[1], which is an amine conjugation of the DHA carrier and the neurotransmitter dopamine[2]. NMI 8739 decreases nitric oxide (NO) generation in LPS-stimulated RAW264.7 macrophages. NMI 8739 produced concentration-dependent suppression of CCL-20, MCP-1, and IL-6 production in RAW264.7 macrophages following LPS stimulation. PGE2 production was suppressed in a concentration-dependent manner, with a 25.3% drop at 100 nM NMI 8739 and a 75% reduction at 1 μM NMI 8739. 2 μM NMI 8739 significantly suppressed IL-6 and CCL-20 release by up to 49% and 37%, respectively [3]. |
| References |
[1]. Gill Higgins, New drugs signal rapid growth of anti-obesity drug market. RESEARCH & DEVELOPMENT. 2 Nov 11K16 No. 1061 [2]. Shashoua VE, et al. N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci. 1996;58(16):1347-57. [3]. Wang Y, et al. N-Docosahexaenoyl Dopamine, an Endocannabinoid-like Conjugate of Dopamine and the n-3 Fatty Acid Docosahexaenoic Acid, Attenuates Lipopolysaccharide-Induced Activation of Microglia and Macrophages via COX-2. ACS Chem Neurosci. 2017 Mar 15;8 |
Solubility Data
| Solubility (In Vitro) |
Ethanol : ~100 mg/mL (~215.68 mM) DMSO : ~65 mg/mL (~140.19 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1568 mL | 10.7840 mL | 21.5680 mL | |
| 5 mM | 0.4314 mL | 2.1568 mL | 4.3136 mL | |
| 10 mM | 0.2157 mL | 1.0784 mL | 2.1568 mL |